NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

微生物治療藥的全球市場 (2019-2030年):市場預測 (各標靶治療領域、地區)、競爭分析

Global Microbiome Therapeutics Market: Focus on Target Therapies, Region (10 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030

出版商 BIS Research Inc. 商品編碼 979807
出版日期 內容資訊 英文 149 Pages
商品交期: 最快1-2個工作天內
價格
微生物治療藥的全球市場 (2019-2030年):市場預測 (各標靶治療領域、地區)、競爭分析 Global Microbiome Therapeutics Market: Focus on Target Therapies, Region (10 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030
出版日期: 2020年12月21日內容資訊: 英文 149 Pages
簡介

全球微生物治療藥的市場規模預計至2030年成長到39億美元的規模。由於DNA定序的大幅度降低成本,各種微生物相關臨床研究過去10年大幅度進行,人們已經學到了很多關於左右人體健康的微生物的集合體所扮演的角色。該市場的成長,預計由於資金籌措的增加,進入經營者的無機成長策略的引進,老年人口增加等,各式因素而受到推動。

本報告提供全球微生物治療藥的市場調查,市場定義和概要,市場成長的各種影響因素分析,市場規模的變化、預測,法律制度,開發平台趨勢,投資、資金籌措趨勢,政府的舉措,標靶治療領域、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊彙整。

摘要整理

第1章 產品定義

第2章 市場範圍

第3章 調查手法

第4章 市場概要

  • 市場規模、成長可能性
  • 發展的變化

第5章 產業考察

  • 法規情形
  • 專利形勢
  • 資金籌措趨勢
  • 開發平台狀況
  • 聯盟趨勢
  • 政府舉措

第6章 市場動態

  • 市場成長的促進因素
  • 市場成長的阻礙因素
  • 市場機會

第7章 競爭考察

  • 主要策略、展開
  • 協同效應
  • 法規認證
  • M&A
  • 市場佔有率分析
  • 成長佔有率分析:市場機會製圖

第8章 市場分析、預測:各標靶治療領域

  • 概要
  • 腸胃、感染疾病
  • 其他

第9章 市場分析、預測:各地區、主要國家

  • 概要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 法國
    • 瑞典
    • 德國
    • 英國
    • 其他
  • 亞太地區
    • 日本
    • 澳洲
    • 中國
    • 印度
    • 其他
  • 其他地區

第10章 企業簡介

  • 4D Pharma plc
  • AOBiome
  • Finch Therapeutics
  • Ferring Pharmaceuticals
  • Rebiotix Inc.
  • Immuron Limited
  • MaaT Pharma
  • Naked Biome
  • OxThera AB
  • Quorum Innovations
  • Sanofi S.A.
  • Seres Therapeutics, Inc.
  • Synthetic Biologics
  • Taisho Pharmaceutical
  • Vedanta Biosciences, Inc.
  • Pendulum Therapeutics
目錄
Product Code: BHL1023SA

"Global Microbiome Therapeutics Market to Reach $3.9 Billion by 2030."

Market Report Coverage - Microbiome Therapeutics

Market Segmentation

  • By Disease Type: Gastrointestinal and Infectious Diseases and Other Diseases
  • By Region: North America, Europe, Asia-Pacific, and Rest-of-the-World

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, U.K., France, Sweden, and Rest-of-Europe
  • Asia-Pacific - China, Australia, Japan, India, and Rest-of-Asia-Pacific
  • Rest-of-the-World

Growth Drivers

  • Increasing adoption of inorganic growth strategies in the market
  • Significant external funding for executing research and therapeutic innovation

Market Challenges

  • Payer uncertainty and outcome-based pricing
  • Insufficient Application-Based Research Hindering Market Pull

Market Opportunities

  • Entry of major players for the development of microbiome therapeutics
  • Growing eminence of microbiome therapeutics in cancer treatment

Key Microbiome Therapeutics Companies Profiled:

4D Pharma plc, AOBiome, Sanofi S.A, Ferring Pharmaceuticals, Finch Therapeutics, Immuron Limited, OxThera AB, among others.

Key Questions Answered in this Report:

  • What is microbiome therapeutics? How have different target therapy area settings for microbiome therapeutics evolved over the centuries?
  • What are the major market drivers, challenges, and opportunities in the global microbiome therapeutics market?
  • What was the global microbiome therapeutics market size in terms of revenue in 2019? How is the market expected to evolve in the upcoming years? What is the expected market size in 2030?
  • How is each segment of the global microbiome therapeutics market expected to grow during the forecast period 2020-2030, and what is the estimated revenue expected to be generated by each of the segments by the end of 2030?
  • What are the developmental strategies implemented by the key players to sustain in the competitive market?
  • What is the growth potential of the global microbiome therapeutics in several countries globally?
  • Which target therapy area segment among the two gastrointestinal and infectious diseases and other therapy areas are offered or being developed by key players such as Taisho Pharmaceuticals, Immuron Limited, Sanofi S.A., and Rebiotix?
  • Which target therapy area segment led the market in 2019 and is expected to dominate the market in 2030, and why?
  • Which region dominated the global microbiome therapeutics market in 2019, and what are the anticipated trends from each of the regions in the forecast period 2020-2030?

Market Overview

Microbiome is defined as the collective genomes of the microbes (composed of fungi, bacteria, bacteriophage, viruses, and protozoa) that live inside and on the body.

Clinical studies on various microbiomes have been significantly growing during the past decade, owing to the considerable reduction in the cost of DNA sequencing, enabling the microbes in their complex mixture to be defined by their genome. Research findings have generated information about the role of the microorganism population in determining human health. The microbiome is found to play a role in inflammatory bowel disease (IBD), allergies, and immune-oncology, among others. Microbiome has become an attractive target for potential therapeutics owing to its extensive role in gastrointestinal and non-gastrointestinal diseases. However, there are challenges associated with microbiome research. Determining the cause-effect relationships and designing microbiome-based therapies that can attain effective results on the human health and microbial community are among such challenges.

Several players, such as Sanofi S.A and Taisho Pharmaceuticals, are currently offering these microbiome therapeutics in the market. The entry of new players in the market, coupled with increased innovation pertaining to therapeutic output maximization with minimal side effects, has transformed the market currently.

The existing market of microbiome therapeutics is favored by multiple factors, which include the rising geriatric populations coupled with the increased financing and the increasing adoption of inorganic growth strategies by key players in the market.

Within the research report, the market is segmented on the basis of target therapy area (gastrointestinal and infectious diseases, and other diseases) and region (North America, Europe, Asia-Pacific, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Competitive Landscape

Major players, including 4D Pharma, Enterome, and Finch Therapeutics, led the number of synergistic developments (partnerships and alliances) witnessed by the market. On the basis of region, Asia-Pacific is expected to retain a leading position throughout the forecast period 2020-2030, followed by Europe. This is a result of the presence of leading industry players in this region, coupled up with soaring clinical activities pertaining to the development of microbiome therapeutics.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Market Scope

  • 2.1 Scope of Work
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Global Microbiome Therapeutics Market: Research Methodology
  • 3.2 Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Market Overview

  • 4.1 Market Size and Future Growth Potential
  • 4.2 Historical Trends

5 Industry Insights

  • 5.1 Regulatory Landscape
    • 5.1.1 Regulatory Requirements for Live Biotherapeutic Products (LBPs)
  • 5.2 Patent Landscape
    • 5.2.1 Patent Filing Analysis
    • 5.2.2 Key Players Patent Portfolio
    • 5.2.3 Key Players Patent Expiration Analysis
  • 5.3 Financing Landscape
    • 5.3.1 Financing Stratification (as Per Raised Financing Value)
    • 5.3.2 Year on Year Financing Analysis (FY2017-3Q2020)
    • 5.3.3 Investment Heat Map
  • 5.4 Pipeline Landscape
    • 5.4.1 Competitive Landscaping
    • 5.4.2 Pipeline Analysis
      • 5.4.2.1 By Developmental Phase
      • 5.4.2.2 By Route of Administration
      • 5.4.2.3 By Type of Microbiome Strategy
      • 5.4.2.4 By Target Therapy Area
  • 5.5 Partnership Landscape
  • 5.6 Government Initiatives

6 Market Dynamics

  • 6.1 Market Drivers
    • 6.1.1 Significant External Funding for Executing Research and Therapeutic Innovation
    • 6.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market
  • 6.2 Market Restraints
    • 6.2.1 Payer Uncertainty and Outcome-Based Pricing
    • 6.2.2 Insufficient Application-Based Research Hindering Market Pull
    • 6.2.3 FMT Manufacturing Issues
  • 6.3 Market Opportunities
    • 6.3.1 Entry of Major Players for the Development of Microbiome Therapeutics
    • 6.3.2 Growing Eminence of Microbiome Therapeutics in Cancer Treatment

7 Competitive Insights

  • 7.1 Key Strategies and Developments
  • 7.2 Synergistic Activities
  • 7.3 Regulatory Accreditations
  • 7.4 Mergers and Acquisitions
  • 7.5 Market Share Analysis
  • 7.6 Growth Share Analysis (Opportunity Mapping)
    • 7.6.1 By Geography
    • 7.6.2 By Company

8 Global Microbiome Therapeutics Market (by Target Therapy Area)

  • 8.1 Overview
  • 8.2 Gastrointestinal and Infectious Diseases
  • 8.3 Other Diseases

9 Global Microbiome Therapeutics Market (by Region)

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 Overview
    • 9.2.2 U.S.
    • 9.2.3 Canada
  • 9.3 Europe
    • 9.3.1 Overview
    • 9.3.2 France
    • 9.3.3 Sweden
    • 9.3.4 Germany
    • 9.3.5 U.K.
    • 9.3.6 Rest-of-Europe
  • 9.4 Asia-Pacific (APAC)
    • 9.4.1 Overview
    • 9.4.2 Japan
    • 9.4.3 Australia
    • 9.4.4 China
    • 9.4.5 India
    • 9.4.6 Rest-of-Asia-Pacific
  • 9.5 Rest-of-the-World
    • 9.5.1 Overview

10 Company Profiles

    • 10.1.1 Overview
  • 10.2 4D Pharma plc
    • 10.2.1 Company Overview
    • 10.2.2 Role of 4D Pharma plc in Global Microbiome Therapeutics Market
    • 10.2.3 Financials
    • 10.2.4 SWOT Analysis
  • 10.3 AOBiome
    • 10.3.1 Company Overview
    • 10.3.2 Role of AOBiome in the Global Microbiome Therapeutics Market
    • 10.3.3 SWOT Analysis
  • 10.4 Finch Therapeutics
    • 10.4.1 Company Overview
    • 10.4.2 Role of Finch Therapeutics in Global Microbiome Therapeutics Market
    • 10.4.3 SWOT Analysis
  • 10.5 Ferring Pharmaceuticals
    • 10.5.1 Company Overview
    • 10.5.2 Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
    • 10.5.3 Company Overview
    • 10.5.4 Role of Rebiotix Inc. in Global Microbiome Therapeutics Market
    • 10.5.5 SWOT Analysis
  • 10.6 Immuron Limited
    • 10.6.1 Company Overview
    • 10.6.2 Role of Immuron in Global Microbiome Therapeutics Market
    • 10.6.3 Financials
    • 10.6.4 SWOT Analysis
  • 10.7 MaaT Pharma
    • 10.7.1 Company Overview
    • 10.7.2 Role of MaaT Pharma in Global Microbiome Therapeutics Market
    • 10.7.3 SWOT Analysis
  • 10.8 Naked Biome
    • 10.8.1 Company Overview
    • 10.8.2 Role of Naked Biome in Global Microbiome Therapeutics Market
    • 10.8.3 SWOT Analysis
  • 10.9 OxThera AB
    • 10.9.1 Company Overview
    • 10.9.2 Role of OxThera AB in Global Microbiome Therapeutics Market
    • 10.9.3 SWOT Analysis
  • 10.1 Quorum Innovations
    • 10.10.1 Company Overview
    • 10.10.2 Role of Quorum Innovations, LLC in Global Microbiome Therapeutics Market
    • 10.10.3 SWOT Analysis
  • 10.11 Sanofi S.A.
    • 10.11.1 Company Overview
    • 10.11.2 Role of Sanofi S.A. in Global Microbiome Therapeutics Market
    • 10.11.3 Financials
    • 10.11.4 Key Insights About the Financial Health of the Company
    • 10.11.5 SWOT Analysis
  • 10.12 Seres Therapeutics, Inc.
    • 10.12.1 Company Overview
    • 10.12.2 Role of Seres Therapeutics, Inc. in Global Microbiome Therapeutics Market
    • 10.12.3 Financials
    • 10.12.4 Key Insights About Financial Health of the Company
    • 10.12.5 SWOT Analysis
  • 10.13 Synthetic Biologics
    • 10.13.1 Company Overview
    • 10.13.2 Role of Synthetic Biologics, Inc. in Global Microbiome Therapeutics Market
    • 10.13.3 Financials
    • 10.13.4 SWOT Analysis
  • 10.14 Taisho Pharmaceutical
    • 10.14.1 Company Overview
    • 10.14.2 Biofermin Pharmaceutical Co. Ltd. (A Subsidiary of Taisho Pharmaceutical)
    • 10.14.3 Company Overview
    • 10.14.4 Role of Taisho Pharmaceutical in Global Microbiome Therapeutics Market
    • 10.14.5 Financial
    • 10.14.6 Key Insights about the Financial Health of the Company
    • 10.14.7 SWOT Analysis
  • 10.15 Vedanta Biosciences, Inc.
    • 10.15.1 Company Overview
    • 10.15.2 Role of Vedanta Biosciences, Inc. in Global Microbiome Therapeutics Market
    • 10.15.3 SWOT Analysis
  • 10.16 Pendulum Therapeutics
    • 10.16.1 Company Overview
    • 10.16.2 Role of Pendulum Therapeutics in Global Microbiome Therapeutics Market
    • 10.16.3 SWOT Analysis

List of Tables

  • Table 5.1: Global Microbiome Therapeutics Market (Key Players Patent Portfolio)
  • Table 5.2: Patent Expiration Analysis
  • Table 5.3: Key Players Investors Portfolio
  • Table 5.4: Key Players Investors Portfolio
  • Table 5.5: Partnership Landscaping
  • Table 5.6: Government Initiatives in Microbiome Therapeutics
  • Table 6.1: Microbiome Collaborations
  • Table 9.1: EU Funding of Microbiome Research Under FP7 and H2020

List of Figures

  • Figure 1: Impact Analysis of Market Drivers and Market Challenges on Global Microbiome Therapeutics Market
  • Figure 2: Global Microbiome Therapeutics Market (by Target Therapy Area), $Million, 2020 and 2030
  • Figure 3: Global Microbiome Therapeutics Market (by Region), $Million, 2019-2030
  • Figure 2.1: Global Microbiome Therapeutics Market Segmentation
  • Figure 3.1: Global Microbiome Therapeutics Market Research Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Global Microbiome Therapeutics Market, $Million, 2019-2030
  • Figure 4.2: Historical Evolution of Microbiome
  • Figure 5.1: Chemistry, Manufacturing, and Control (CMC) Information of LBPs by FDA
  • Figure 5.2: Patent Landscape of Microbiome Therapeutics Market (by Company and Region)
  • Figure 5.3: Key Players Financing Stratification
  • Figure 5.4: Financing Analysis, $Million, FY2017-3Q2020
  • Figure 5.5: Number of Pipeline Candidates (by Developmental Phase)
  • Figure 5.6: Number of Pipeline Candidates (by Route of Administration)
  • Figure 5.7: Number of Pipeline Candidates (by Type of Product)
  • Figure 5.8: Number of Pipeline Candidates (by Target Therapy Area)
  • Figure 6.1: Market Dynamics of Global Microbiome Therapeutics Market
  • Figure 6.2: Financing Activities Breakout, 2017-2019
  • Figure 6.3: Overall Financing Raised by Microbiome Companies, $Million, January 2017 - 3Q 2020
  • Figure 6.4: Synergistic Activities, 2017-2019
  • Figure 7.2: Synergistic Activities Share (by Company), January 2017-October 2020
  • Figure 7.3: Accreditations Share (by Company), January 2017- October 2020
  • Figure 7.4: Mergers and Acquisitions (by Company), January 2017- October 2020
  • Figure 7.5: Market Share Analysis for the Global Microbiome Therapeutics Market, 2018 and 2019
  • Figure 7.6: Growth Share Analysis (by Geography)
  • Figure 7.7: Growth Share Analysis (by Company)
  • Figure 8.1: Global Microbiome Therapeutics Market (by Target Therapy Area), 2020 and 2030
  • Figure 8.2: Number of Pipeline Candidates for Gastrointestinal and Infectious Diseases Indications
  • Figure 8.3: Global microbiome therapeutics market (Gastrointestinal and Infectious Diseases), 2019-2030
  • Figure 8.4: Global Microbiome Therapeutics Market (Other Diseases), 2023-2030
  • Figure 9.1: Global Microbiome Therapeutics Market (by Region), 2020 and 2030
  • Figure 9.2: North America Microbiome Therapeutics Market, 2019-2030
  • Figure 9.3: North America: Market Dynamics
  • Figure 9.4: North America Microbiome Therapeutics Market (by Country), 2020 and 2030
  • Figure 9.5: U.S. Microbiome Therapeutics Market, 2019-2030
  • Figure 9.6: Canada Microbiome Therapeutics Market, 2019-2030
  • Figure 9.7: Europe Microbiome Therapeutics Market, 2019-2030
  • Figure 9.8: Europe: Market Dynamics
  • Figure 9.9: Europe Microbiome Therapeutics Market (by Country), 2020 and 2030
  • Figure 9.10: France Microbiome Therapeutics Market, 2019-2030
  • Figure 9.11: Sweden Microbiome Therapeutics Market, 2019-2030
  • Figure 9.12: Germany Microbiome Therapeutics Market, 2019-2030
  • Figure 9.13: U.K. Microbiome Therapeutics Market, 2019-2030
  • Figure 9.14: Rest-of-Europe Microbiome Therapeutics Market, 2019-2030
  • Figure 9.15: Asia-Pacific Microbiome Therapeutics Market, 2019-2030
  • Figure 9.16: Asia-Pacific: Market Dynamics
  • Figure 9.17: Asia-Pacific Microbiome Therapeutics Market (by Country), 2020 and 2030
  • Figure 9.18: Japan Microbiome Therapeutics Market, 2019-2030
  • Figure 9.19: Australia Microbiome Therapeutics Market, 2019-2030
  • Figure 9.20: China Microbiome Therapeutics Market, 2019-2030
  • Figure 9.21: India Microbiome Therapeutics Market, 2019-2030
  • Figure 9.22: Rest-of-Asia-Pacific Microbiome Therapeutics Market, 2019-2030
  • Figure 9.23: Rest-of-the-World Microbiome Therapeutics Market, 2019-2030
  • Figure 10.1: Total Number of Companies Profiled
  • Figure 10.2: 4D Pharma plc: Overall Product Portfolio
  • Figure 10.3: 4D Pharma plc.: Overall Financials, 2018-2019
  • Figure 10.4: 4D Pharma plc: SWOT Analysis
  • Figure 10.5: AOBiome.: Overall Product Portfolio
  • Figure 10.6: AOBiome: SWOT Analysis
  • Figure 10.7: Finch Therapeutics: Overall Product Portfolio
  • Figure 10.8: Finch Therapeutics: SWOT Analysis
  • Figure 10.9: Rebiotix Inc.: Overall Product Portfolio
  • Figure 10.10: Rebiotix Inc.: SWOT Analysis
  • Figure 10.11: Immuron: Overall Product Portfolio
  • Figure 10.12: Immuron: Overall Financials, 2018-2020
  • Figure 10.13: Immuron: Research and Development Expenditure, 2018-2020
  • Figure 10.14: Immuron: SWOT Analysis
  • Figure 10.15: MaaT Pharma.: Overall Product Portfolio
  • Figure 10.16: MaaT Pharma: SWOT Analysis
  • Figure 10.17: Naked Biome: Overall Product Portfolio
  • Figure 10.18: Naked Biome: SWOT Analysis
  • Figure 10.19: OxThera AB: Overall Product Portfolio
  • Figure 10.20: OxThera AB: SWOT Analysis
  • Figure 10.21: Quorum Innovations, LLC: Overall Product Portfolio
  • Figure 10.22: Quorum Innovations, LLC: SWOT Analysis
  • Figure 10.23: Sanofi S.A.: Overall Product Portfolio
  • Figure 10.24: Sanofi S.A.: Overall Financials, 2017-2019
  • Figure 10.25: Sanofi S.A.: Revenue (by Segment), 2017-2019
  • Figure 10.26: Sanofi S.A.: Region Revenue, 2017-2019
  • Figure 10.27: Sanofi S.A.: Research and Development Expenditure, 2017-2019
  • Figure 10.28: Sanofi S.A.: SWOT Analysis
  • Figure 10.29: Seres Therapeutics, Inc.: Overall Product Portfolio
  • Figure 10.30: Seres Therapeutics, Inc.: Overall Financials, 2017-2019
  • Figure 10.31: Seres Therapeutics Inc.: R&D Expenditure, 2017-2019
  • Figure 10.32: Seres Therapeutics Inc.: SWOT Analysis
  • Figure 10.33: Synthetic Biologics, Inc.: Overall Product Portfolio
  • Figure 10.34: Synthetic Biologics, Inc.: Overall Financials, 2017-2019
  • Figure 10.35: Synthetic Biologics, Inc.: SWOT Analysis
  • Figure 10.36: Taisho Pharmaceutical Co., Ltd.: Overall Product Portfolio
  • Figure 10.37: Taisho Pharmaceutical Co., Ltd.: Overall Financials, 2017-2019
  • Figure 10.38: Taisho Pharmaceutical Co., Ltd. (by Segment), 2017-2019
  • Figure 10.39: Taisho Pharmaceutical Co., Ltd. (by Region), 2019
  • Figure 10.40: Taisho Pharmaceutical Co., Ltd.: R&D Expenditure, 2018-2019
  • Figure 10.41: Taisho Pharmaceutical Co., Ltd.: SWOT Analysis
  • Figure 10.42: Vedanta Biosciences, Inc.: Overall Product Portfolio
  • Figure 10.43: Vedanta Biosciences, Inc.: SWOT Analysis
  • Figure 10.44: Whole Genome Inc.: Overall Product Portfolio
  • Figure 10.45: Whole Biome Inc.: SWOT Analysis